/Investor DB

Solas BioVentures — 2023 Investments

2 investments dated 2023 · listed companies and verified rows first · show all

Arrivo BioVenturesarrivobio.cominSeries B · Nov 2023 · $45M

Arrivo Bio develops novel, disease-modifying medicines targeting the root cause of hard-to-treat diseases for which few effective treatment options exist.

BiotechMedical DevicesMorrisville, US

Karen Adams(Executive Officer)Stephen E. Butts(Executive Officer)

Co-investorsRex Health VenturesOrlando Health Ventures

Dimension Biodimension.bioinFeb 2023

Dimension Bio is a biotechnology company developing regenerative therapeutics using its BioNidum platform, which combines materials science, 3D printing, and digital manufacturing to produce implantable and injectable biosynthetic scaffolds that promote tissue healing.

BiotechHealthtechMedical DevicesNew MaterialsChicago, US

Caralynn Nowinski Collens(Co-founder & CEO)inRamille Shah, Ph.D.(Co-founder & CSO)Ramille Shah(Co-founder & CSO)Adam Jakus(Co-Founder)inRamille S.(Founder)inLarry Weinstein(SVP, Manufacturing & Quality Operations)

Co-investorsAlumni VenturesBetter Ventures Central LlcGaingelsHarvard Business Angels of ChicagoHAWKTAILKdT Ventures+5 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.